Literature DB >> 20736364

HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.

Aliccia Bollig-Fischer1, Michele Dziubinski, Alaina Boyer, Ramsi Haddad, Craig N Giroux, Stephen P Ethier.   

Abstract

Activated oncogenes are the dominant drivers of malignant progression in human cancer, yet little is known about how the transformation from proto-oncogene to activated oncogene drives the expression of transformed phenotypes. An isogenic model of HER-2-mediated transformation of human mammary epithelial cells was used along with HER-2-amplified human breast cancers to investigate how HER-2 activation alters its properties as a signaling molecule and changes the networks of HER-2-regulated genes. Our results show that full oncogenic activation of HER-2 is the result of a transition in which activated HER-2 acquires dominant signaling properties that qualitatively alter the network of genes regulated by the activated oncogene compared with the proto-oncogene. Consequently, gene expression programs related to invasion, cell stress, and stemness become regulated by HER-2 in a manner not observed in nontransformed cells, even when HER-2 is overexpressed. Our results offer novel insights into biological processes that come under the control of HER-2 after it acquires full oncogenic potential. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20736364      PMCID: PMC3858175          DOI: 10.1158/0008-5472.CAN-10-1529

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  The molecular basis of oncogenes and tumor suppressor genes.

Authors:  R A Weinberg
Journal:  Ann N Y Acad Sci       Date:  1995-06-30       Impact factor: 5.691

3.  Importance of extended growth potential and growth factor independence on in vivo neoplastic potential of primary rat mammary carcinoma cells.

Authors:  S P Ethier; K C Cundiff
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

4.  Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.

Authors:  Luanda P Grazette; Wolfgang Boecker; Takashi Matsui; Marc Semigran; Thomas L Force; Roger J Hajjar; Anthony Rosenzweig
Journal:  J Am Coll Cardiol       Date:  2004-12-07       Impact factor: 24.094

5.  Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells.

Authors:  Bart S Hendriks; Gayla Orr; Alan Wells; H Steven Wiley; Douglas A Lauffenburger
Journal:  J Biol Chem       Date:  2004-11-29       Impact factor: 5.157

6.  Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response.

Authors:  Harish Shankaran; H Steven Wiley; Haluk Resat
Journal:  Biophys J       Date:  2006-03-13       Impact factor: 4.033

7.  Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.

Authors:  Jitesh P Jani; Richard S Finn; Mary Campbell; Kevin G Coleman; Richard D Connell; Nicolas Currier; Erling O Emerson; Eugenia Floyd; Shawn Harriman; John C Kath; Joel Morris; James D Moyer; Leslie R Pustilnik; Kristina Rafidi; Sherry Ralston; Ann Marie K Rossi; Stefanus J Steyn; Larry Wagner; Steven M Winter; Samit K Bhattacharya
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

8.  Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.

Authors:  T G Ram; C A Dilts; M L Dziubinski; L J Pierce; S P Ethier
Journal:  Mol Carcinog       Date:  1996-03       Impact factor: 4.784

Review 9.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

Authors:  Antony W Burgess; Hyun-Soo Cho; Charles Eigenbrot; Kathryn M Ferguson; Thomas P J Garrett; Daniel J Leahy; Mark A Lemmon; Mark X Sliwkowski; Colin W Ward; Shigeyuki Yokoyama
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

10.  Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.

Authors:  E Peles; R B Levy; E Or; A Ullrich; Y Yarden
Journal:  EMBO J       Date:  1991-08       Impact factor: 11.598

View more
  12 in total

1.  A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.

Authors:  Courtney R Giordano; Kelly L Mueller; Laura J Terlecky; Kendra A Krentz; Aliccia Bollig-Fischer; Stanley R Terlecky; Julie L Boerner
Journal:  Exp Cell Res       Date:  2012-06-08       Impact factor: 3.905

2.  Development and implementation of the SUM breast cancer cell line functional genomics knowledge base.

Authors:  Stephen P Ethier; Stephen T Guest; Elizabeth Garrett-Mayer; Kent Armeson; Robert C Wilson; Kathryn Duchinski; Daniel Couch; Joe W Gray; Christiana Kappler
Journal:  NPJ Breast Cancer       Date:  2020-07-21

3.  Modeling time-dependent transcription effects of HER2 oncogene and discovery of a role for E2F2 in breast cancer cell-matrix adhesion.

Authors:  Aliccia Bollig-Fischer; Luca Marchetti; Cristina Mitrea; Jiusheng Wu; Adéle Kruger; Vincenzo Manca; Sorin Drăghici
Journal:  Bioinformatics       Date:  2014-07-15       Impact factor: 6.937

4.  Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach.

Authors:  Hanna Björkelund; Lars Gedda; Magnus Malmqvist; Karl Andersson
Journal:  Mol Clin Oncol       Date:  2012-10-30

Review 5.  ER stress and impaired autophagy flux in neuronal degeneration and brain injury.

Authors:  Yan Yin; George Sun; Eric Li; Kirill Kiselyov; Dandan Sun
Journal:  Ageing Res Rev       Date:  2016-09-01       Impact factor: 10.895

Review 6.  Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance.

Authors:  Ethan B Butler; Yuhua Zhao; Cristina Muñoz-Pinedo; Jianrong Lu; Ming Tan
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

7.  Oncogene activation induces metabolic transformation resulting in insulin-independence in human breast cancer cells.

Authors:  Aliccia Bollig-Fischer; T Gregory Dewey; Stephen P Ethier
Journal:  PLoS One       Date:  2011-03-17       Impact factor: 3.240

Review 8.  The role of n-3 polyunsaturated fatty acids in the prevention and treatment of breast cancer.

Authors:  Jiajie Liu; David W L Ma
Journal:  Nutrients       Date:  2014-11-18       Impact factor: 5.717

9.  Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells.

Authors:  Graziela Rosa Ravacci; Maria Mitzi Brentani; Tharcisio Citrângulo Tortelli; Raquel Suzana M M Torrinhas; Jéssica Reis Santos; Angela Flávia Logullo; Dan Linetzky Waitzberg
Journal:  Biomed Res Int       Date:  2015-11-12       Impact factor: 3.411

10.  Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.

Authors:  Bin Bao; Cristina Mitrea; Priyanga Wijesinghe; Luca Marchetti; Emily Girsch; Rebecca L Farr; Julie L Boerner; Ramzi Mohammad; Greg Dyson; Stanley R Terlecky; Aliccia Bollig-Fischer
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.